Hepatitis B Surface Antigen ELISA Kit

Name: Hepatitis B Surface Antigen ELISA Kit
SKU: DEIA001
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

blood

Species Reactivity

Human

Detection Method

sandwich

Intended Use

1. For screening of blood donors.
2. As an aid in the diagnosis of liver disease.

Contents of Kit

1. Coated Microplate: 1 plate (96 tests), twelve 8-well strips per plate.
2. Conjugate: 1 vial of 6.2 mL (HRP-labeled anti-HBs).
3. Positive Control: 1 vial of 1.0 mL.
4. Negative Control: 1 vial of 1.0 mL.
5. Washing solution: 1 bottle of 40 mL concentrated.
6. Chromogen A: 1 vial of 8.0 mL (contains hydro-peroxide).
7. Chromogen B: 1 vial of 8.0 mL (contains TMB).
8. Stopping solution: 1 vial of 7.0 mL (0.5M sulphuric acid).

Storage

1. If kept at 2 to 8°C, all the test reagents are stable until the expiry date printed on the kit.
2. When the aluminum bag has been opened, the unused strips can be safely stored at 2-8°C in the sealable plastic pouch along with the silica gel placed inside for about two weeks.

Sensitivity

Human Anti-HBsAg ELISA Kit

General Description

CD HBsAg is an in vitro diagnostic kit for the detection of hepatitis B surface antigen (HBsAg) in human serum or plasma.

Citations

Have you cited DEIA001 in a publication? Let us know and earn a reward for your research.

Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

Zhang M, Mouzannar K, Zhang Z, Teraoka Y, Piotrowski J, Ishida Y, Tateno-Mukaidani C, Saito T, Abe-Chayama H, Chayama K, Liang TJ

PLoS Pathog2025 Jan 9PubMed ID:39787208Read Article

Applications: ELISA
Reactive species: HBV
"Abstract: HBV genotype A has two major subtypes, A1 (commonly in Africa) and A2 (commonly in Europe) with only 4% nucleotide differences. Individuals infected with these two subtypes appear to have different clinical manifestations and virologic features. Whether such a difference results from the virus or host has not been established. Using HBV generated from molecule clones of subtypes A1 and A2 in cell culture (HBVcc), we demonstrate that HBVcc of subtypes A1 and A2 can be passaged in vitro and in vivo and respond equally well to human IFN-α treatment. HBVcc passaged in human liver chimeric mice (HBVmp) infected human hepatocytes more efficiently than that of the original HBVcc. Subtype A2 showed a much higher viral replication level than that of subtype A1. Mechanistic investigations using constructs with chimeric A1/A2 sequences and specific mutations indicated that subtype A2 has an inherently higher replication phenotype due to specific polymorphisms in the HBx gene resulting in amino acid variations. Studies of HBx expression demonstrated that A1 HBx is expressed at a much lower level than that of A2 HBx. Mutagenesis studies identified two HBx amino acid variations responsible for the observed phenotypic difference. Using AlphaFold2, we generated structural models of HBx proteins of A1 and A2. Superposition of the two models reveal that the overall structural motifs are similarly aligned, except for the C-terminal peptides diverging between the A1 and A2 models, possibly explaining their functional difference. In conclusion, using various in vitro and in vivo models, here we show that subtype A2 has an inherently higher replication phenotype due to polymorphisms in HBx that result in possible differences in structure and expression level of the two subtype HBx proteins. This genotypic difference potentially explains the reported clinical differences between the two subtypes as well as providing a previously unrecognized association between viral sequence variations and clinical manifestations of HBV infection in humans."
Article snippet: HBeAg and HBsAg in cell culture supernatants was measured by ELISA kits (Creative-Diagnostics, NY, USA) according to the protocol. Samples outside the assay linear range were diluted and re-assayed.

1.3X genome-length HBV subtype A1 or A2 replicative competent construct plasmid was transient transfected into HepG2-NTCP and PXB-cells. Culture media on day 7 after transient transfection were harvested and assayed for HBeAg and HBsAg with ELISA kit. (Zhang M, <i>et al</i>, 2025)

Figure 1. Mechanistic studies of higher replication phenotype of HBV subtype A2.

Documents

pdf COA

pdf SDS

pdf Datasheet

Reagents for HBV Serology Testing and Vaccine Research

QA & Reviews

Customer Reviews

References

Quasispecies characteristic in "a" determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study

GUT

Authors: Xiao, Yiwei; Sun, Kuixia; Duan, Zhongping; Liu, Zhixiu; Li, Yi; Yan, Ling; Song, Yarong; Zou, Huaibin; Zhuang, Hui; Wang, Jie; Li, Jie

Abstract

Objective This study was performed to explore the correlation between the characteristics of hepatitis B virus (HBV) quasispecies in HBV-infected pregnant women and the risk of immunoprophylaxis failure for their infants. Design In this prospective nested case-control study, the characteristics of HBV quasispecies in mothers whose infants were immunoprophylaxis success (control group) and those whose infants were immunoprophylaxis failure (case group) were analysed by the clone-based sequencing of full-length HBV genome and next-generation sequencing (NGS) of "a" determinant region, and were compared between the two groups. Results The quasispecies characteristics including mutant frequency, Shannon entropy and mean genetic distance at amino acid level of "a" determinant region were significantly lower in case group than that in control group, using the full-length HBV genome clone-based sequencing assay. These results were confirmed by NGS assay. Notably, we discovered that the differences were also significant at nucleotide level by NGS assay. Furthermore, the risk of immunoprophylaxis failure could be predicted by analysing the three HBV quasispecies characteristics either at nucleotide level or at amino acid level of "a" determinant region, and the corresponding predictive values were tentatively set up. Conclusions HBV quasispecies with a more complex mutant spectrum in "a" determinant region might be more vulnerable to extinct through mother-to-child-transmission (MTCT). More importantly, analysing HBV quasispecies characteristics in pregnant women with high HBV DNA load might be helpful to predict the high-risk population of immunoprophylaxis failure, and consequently provide accurate intervention against MTCT of HBV.

Prognostic value of chronic hepatitis B virus infection in patients with breast cancer in a hepatitis B virus endemic area

ANNALS OF TRANSLATIONAL MEDICINE

Authors: Xiao, Weikai; Zhou, Ying; Yu, Ping; Yang, Anli; Zheng, Shaoquan; Tang, Hailin; Xie, Xiaoming

Abstract

Background: Except for hepatocellular carcinoma, chronic hepatitis B virus (HBV) infection has also been reported to be associated with increased morbidity and mortality of other cancers. However, the impact of chronic HBV infection on the prognosis of breast cancer (BC) remains unclear. Our study aimed to evaluate the prognostic value of HBV infection for BC in an endemic area of HBV in China. Methods: There was a total of 1,904 patients with early BC who underwent mastectomy or breast-conserving surgery enrolled in our study. HBV infection on overall survival (OS) and hepatic metastasis-free survival (I IMFS) was the main research indicator for this study. Results: A total of 212 patients (11.1%) were identified with chronic HBV infection due to serum hepatitis B surface antigen (H BsAg) positive. HBsAg-positive patients had inferior OS (84.9% vs. 90.4%, P=0.005) and HMFS (92.5% vs. 97.1%, P=0.016) at 5 years than HBsAg-negative patients. Chronic HBV infection was an independent predictor of poor OS in patients with BC [multivariate analysis; hazard ratio (I IR), 1.52; P=0.038], but not for HMFS. Subgroup analysis showed that chronic HBV infection was an unfavorable independent prognostic factor for OS in patients with stage II/III BC (HR, 1.59; P=0.025). The 5-year OS and HMFS rates of HBsAg-positive patients were 81.9% and 90.5% for patients with stage II/III BC, while those rates of HBsAg-negative patients were 88.5% and 96.3%, respectively. In stage I patients, there was no significant difference in 5-year OS (95.8% vs. 97.1%; P=0.629) and HMFS (100.0% vs. 99.0%; P=0.447). Conclusions: In conclusion, chronic HBV infection predicts a worse prognosis in patients with stage BC, but not stage I BC.